Share

Profile & Fundamentals

Sanofi Profile & Fundamentals

Name: Sanofi financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Company profile record

Sanofi SA

Common Stock · Health Care · Pharmaceuticals

Official website

Company

Company / asset: Sanofi SA
Security type: Common Stock
Sector: Health Care
Industry: Pharmaceuticals
HQ: 🇫🇷 France
Head office: 46, avenue de la Grande ArmEe, Paris, France, 75017

Leadership & scale

Chief executive: Ms. Belen Garijo Lopez M.D.
CEO year born: 1960
Full-time employees: 74.8K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-09-12

Market Cap: EUR 88.6B
P/E: 13.1x
Revenue (Q2 26): EUR 12.3B
Profit (Q2 26): EUR 343.0M
Dividend Yield: 4.2%
Revenue (FY 25): EUR 46.7B
Shares in public float: 1.1B
Insider ownership: 10.31%

Reporting & identifiers

Symbol: SAN.PAR
Listing: 🇫🇷 France | Dividend Tax: 25%
Ticker Currency: EUR
Income Statement Currency: EUR
Balance Sheet Currency: EUR
Cash Flow Currency: EUR
EPS Currency: EUR
Contract Type: SPOT
ISIN: FR0000120578
Asset ID: equity_56b28eb6-34ca-56e9-a0de-0798b00e74da

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company is showing incredible financial strength, highlighted by a massive surge in free cash flow that makes it a highly secure investment. While recent quarterly net income has shown some temporary declines due to heavy investments in research and development, the overall cash-generation engine remains spectacular. Most reports agree that the company's ability to turn sales into actual cash is outstanding, which easily supports its generous dividend payments and stock buybacks. However, there is some disagreement about future profit growth. Some experts worry that profit-sharing agreements with partners and rising costs will limit how much money actually reaches the bottom line, while others believe that aggressive will easily boost earnings per share. Overall, the company's massive cash flow provides a strong safety net for everyday investors.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company maintains highly impressive profit margins, driven by the strong pricing power of its essential healthcare products. Gross margins are incredibly stable at around seventy percent, showing that the company can easily pass on rising costs to customers. However, there is a clear clash of opinions regarding future operating margins. Some analysts warn that profit-sharing agreements on its top-selling drug, combined with government price controls in the United States and Europe, will squeeze profitability over the coming years. On the other hand, optimists argue that spinning off lower-margin divisions and using artificial intelligence to cut research costs will protect and even expand . Despite these disagreements, the current low stock price suggests that the market is being far too pessimistic about the company's long-term profitability.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	36,777,760,000	6,100,300,000	4,991,540,000	69.16	18.82	13.57	16.59
2017-12-31	43,102,990,000	6,453,370,000	10,015,040,000	68.4	16.02	23.24	14.97
2018-12-31	40,671,780,000	4,069,800,000	4,908,840,000	68.27	13.11	12.07	10.01
2019-12-31	42,146,720,000	6,639,360,000	3,084,480,000	68.18	8.11	7.32	15.75
2020-12-31	45,590,180,000	6,508,700,000	14,998,680,000	67.6	37.77	32.9	14.28
2021-12-31	44,659,500,000	9,666,060,000	7,094,220,000	68.73	20.74	15.89	21.64
2022-12-31	43,125,280,000	8,907,750,000	8,956,970,000	70.55	32.62	20.77	20.66
2023-12-31	45,219,900,000	9,502,900,000	5,940,000,000	69.3	31.57	13.14	21.01
2024-12-31	46,057,440,000	6,121,440,000	5,782,400,000	70.21	32.63	12.55	13.29
2025-12-31	54,657,720,000	10,515,960,000	9,141,210,000	72.07	20.54	16.72	19.24

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	9.51	Trailing four quarters
2024-12-31	20.46	Trailing four quarters
2023-12-31	20.84	Trailing four quarters
2022-12-31	13.5	Annual net income
2021-12-31	17.77	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	1,252,900,000
2018-01-01	1,245,600,000
2019-01-01	1,253,100,000
2020-01-01	1,255,100,000
2021-01-01	1,254,900,200
2022-01-01	1,257,884,200
2023-01-01	1,253,600,000
2024-01-01	1,253,600,000
2025-01-01	1,212,700,000
2026-01-01	1,196,600,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.